v3.26.1
Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 27, 2024
Feb. 28, 2026
Jun. 30, 2025
Oct. 31, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Oct. 14, 2025
Jun. 27, 2025
Mar. 20, 2025
Nov. 30, 2024
Nov. 16, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenue from Contract with Customer, Excluding Assessed Tax         $ 961,138 $ 966,630 $ 2,072,094 $ 1,360,202              
Restricted cash and cash equivalents         1,555,649   1,555,649                
Deferred Tax Asset, In-Process Research and Development         1,555,649   1,555,649                
Milestone payment     $ 250,000                        
Payments for royalties   $ 200,000                          
Gates Foundation [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Accounts receivable                           $ 3,092,136  
Revenue from Contract with Customer, Excluding Assessed Tax         253,186   506,154                
Cost of revenue         229,977   460,596                
Grant receivable         3,092,136   3,092,136               $ 3,092,136
Fondazione Biotecnopolo Di Siena Fbs [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Accounts receivable         991,607   991,607                
Grant receivable                         $ 4,500,000    
Grant receivable                         $ 2,432,756    
CEPI [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenue from Contract with Customer, Excluding Assessed Tax         584,066   818,464                
Cost of revenue         630,866   851,929                
Proliant Agreement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Cost of revenue         0   253,000                
License and development initial term 10 years                            
License and development extension term 3 years                            
Initial up front payment                       $ 500,000      
Second payment upon completion transfer                       $ 500,000      
Final payment upon meeting certain productivity threshold                     $ 500,000        
Research and development revenue                 $ 227,000            
Research and development revenue                 142,300            
Deferred revenue                 273,000            
Revenue         $ 0   $ 273,000                
Inzymes Agreement Aps [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Non refundable upfront payment received       $ 600,000                      
Deferred license revenue                 $ 25,000            
Inzymes Agreement Aps [Member] | Research and Development Arrangement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred license revenue                   $ 890,169